Biotech China 2014

View Profile


Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors
1. 2009 Cytidine Deaminase Single Nucleotide Polymorphism is Predictive of Toxicity from Gemcitabine in Patients with Pancreatic Cancer from RTOG 9704. Oral presentation, ASCO
2. 2009 Relative sensitivities of U87 glioblastoma xenografts expressing wildtype EGFR to the receptor tyrosine kinase inhibitors, vandetanib and cediranib combined with temozolamide and radiotherapy. American Association for Cancer Research 2009 Annual Meeting.
3. 2009 A phase I trial using patupilone (epothilone B) and concurrent radiotherapy for CNS malignancies. CNS malignancies
4. 2009 NF-kB inhibitors alleviate and proteasome inhibitors exacerbate radiation toxicity in zebrafish embryos Submitted, Cancer Research.
5. 2009 Resistance To Methotrexate: Experimental And Clinical. In: Drug Resistance Mechanisms And Reversal
6. 2009 Sequence Analysis Of A Human Gene Responsible For Drug Resistance: A Rapid Method For Manual And Automated Direct Sequencing Of Products The Polymerase Chain Reaction. BioTechniques
7. 2009 Normalization of Tumor Vasculature and Improvement of Radiation Humana Press
8. 2008 Robotically Assisted Platform for Brachytherapy and Intratumoral Delivery. Sino-American Network in Therapeutic Radiation and Oncology Symposium
9. 2008 Investigation of radioactive seed immobilization techniques for interstitial brachytherapy procedure: preliminary study. The 22nd international congress and exhibition computer assisted radiology and surgery (CARS),
10. 2008 Real-time control strategy for collision avoidance and seed deposition in EUCLIDIAN brachytherapy robotic system The 22nd international congress and exhibition computer assisted radiology and surgery (CARS),
11. 2008 An Update on Correlative Molecular Endpoints from RTOG 0211: Phase I/II Study of Gefitinib + Radiation for Newly Diagnosed Glioblastoma 13th Annual Meeting of the Society of Neuro-Oncology.
12. 2008 Samarium 153 Lexidoronam Complex for treatment of occult bony metastasis in high-risk, clinically non-metastatic prostate cancer: The first report of a completed phase I Trial. American Society Therapeutic Radiation Oncology
13. 2008 Atlas-Based Segmentation in Prostate IMRT: timesavings in the clinical workflow. American Society Therapeutic Radiation Oncology
14. 2008 Phase I Trial Using the Proteasome Inhibitor Bortezomid (Velcade) and Concurrent Chemoradiotherapy for Head and Neck Malignancies. American Society Therapeutic Radiation Oncology
15. 2008 ZD6474 enhances radiation therapy in human glioblastoma xenografts which contain the EGFRvIII mutation or overexpress wtEGFR. Radiation Research Society
16. 2008 Hypoxia in prostate cancer: observation to intervention. Lancet Oncology
17. 2008 Combining VEGFR/EGFR blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma by targeting tumor cells and tumor associated endothelial cells. Clinical Cancer Research, Clin Cancer Res. 2008 Sep 1;14(17):5466-75.
18. 2008 Radioactive seed immobilization techniques for interstitial brachytherapy. International Journal of Computer Assisted Radiology and Surgery.
19. 2008 Differential radiation sensitization of human cervical cell lines by the proteasome inhibitor bortezomib. Arch Gynecol Obstet.
20. 2008 Biologically conformal treatment: biomarkers and functional imaging in radiation oncology. Future Oncology, Vol. 4, No. 5
21. 2008 A phase I trial using the proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for CNS malignancies. International Journal of Radiation Oncology, Biology, Physics
22. 2008 The Technique of Outpatient Placement of Intraprostatic Fiducial Markers Prior to External Beam Radiation Therapy. In press, Urology.
23. 2008 Changes in Gene Expression Predicting Local Control in Cervical Cancer: Results from RTOG 0128. Accepted, Clinical Cancer Research.
24. 2008 Poly(ADP-ribose) Polymerase-1 Inhibition-Mediated Enhancement of Radiation and Temozolomide in Glioblastoma Underlying Mechanisms. Submitted, Cancer Research.
25. 2008 Influence of EGFR and PTEN expression levels on radioresistance in U87 glioblastoma transfectants. Submitted International Journal of Radiation Oncology, Biology, Physics.
26. 2008 Human Equilibrative Nucleoside Transporter 1 (hENT1) levels predict response to gemcitabine in patients with resected pancreatic cancer In press, Gastroenterology.
27. 2008 “Calibration of Image-guided Robotic System for Prostate Brachytherapy” Medical Physics, Vol.35, No.6, AAPM Annual Meeting Issue, pp. 2970
28. 2008 “Parameter Optimization for Brachytherapy Robotic Needle Insertion and Seed Deposition”, Medical Physics, Vol.35, No.6, AAPM Annual Meeting Issue, pp. 2865
29. 2008 Validation of Lysyl Oxidase (LOX) as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma (HNSCC) – Radiation Therapy Oncology Group (RTOG) Trial 9003. ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer.
30. 2008 Correlative molecular endpoints from RTOG 0211: Phase I/II study of Gefitinib + radiation for newly diagnosed glioblastoma (GBM). ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer.
31. 2008 A phase I trial of hypofractionated stereotactic radiation therapy with sunitinib in recurrent high grade gliomas. Society of Neuro- Oncology 13th Annual Meeting
32. 2008 Acoustic radiation force as an early discriminator of vessel normalization after anti-angiogenic therapy in a murine tumor model. Sino-American Network in Therapeutic Radiation and Oncology Symposium
33. 2008 The selective PARP inhibitor, CEP-9722 exhibits significant radiosensitization against radioresistant U87 human glioblastoma xenografts and does not potentiate radiation-induced normal tissue toxicity. AACR Annual Meeting
34. 2008 Improvement of Colorectal Tumor Control by Combining an Erbitux-Sensitive Tumor with Radiotherapy and the Chemotherapeutic Agents, Oxaliplatin and Irinotecan (CPT-11) AACR Annual Meeting
35. 2008 Tumor-Associated Macrophages (TAMs) are Poor Prognostic Indicators in Pancreatic Cancer Digestive Disease Week,
36. 2008 Phase I Study of Gefitinib (Iressa) In Combination with Hypofractionated Thoracic Radiation Therapy (HRT) with Stereotactic Body Frame (SBF) Immobilization in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). ESMO/IASLC
37. 2008 Phase I trial of Bortezomib (Velcade), cisplatin and radiotherapy for advanced head and neck cancer. ASCO
38. 2008 A phase I trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies. ASCO
39. 2008 Combining plasma TGF-β1 and lung dosimetric factor to predict radiation-induced lung toxicity in patients with non-small cell lung cancer: A combined analysis from Beijing and Michigan ASCO
40. 2008 Robotic system for image-guided prostate seed implant. Accepted, American Society for Brachytherapy Annual Meeting
41. 2008 A phase I trial of hypofractionated stereotactic radiation therapy with sunitinib in recurrent high-grade gliomas. American Society Therapeutic Radiation Oncology
42. 2008 Changes in Gene Expression Predicting Local Control in Cervical Cancer: Results from RTOG 0128. American Society Therapeutic Radiation Oncology
43. 2008 ERCC1, COX-2, and p53 expression in patients with locally advanced cervical cancer treated with chemoradiotherapy and celecoxib: a quantitative immunohistochemical analysis of RTOG 0128 American Society Therapeutic Radiation Oncology
44. 2008 A Model for Distant Metastasis Incorporating Tissue Biomarkers from Prostate Cancer Patients In Radiation Therapy Oncology Group (RTOG) 92-02. American Society Therapeutic Radiation Oncology
45. 2008 An Update on Correlative Molecular Endpoints from RTOG 0211: Phase I/II Study of Gefitinib + Radiation for Newly Diagnosed Glioblastoma Patients. American Society Therapeutic Radiation Oncology
46. 2008 A phase I trial of patupilone (epothilone B) and concurrent radiotherapy for CNS malignancies. American Society Therapeutic Radiation Oncology
47. 2008 What is the feasibility of Atlas-based IMRT planning-what is the accuracy if we used the best matched IMRT plan that we apply directly? American Society Therapeutic Radiation Oncology
48. 2008 Inhibition of p73 function by Pifithrin-a as revealed by studies in zebrafish embryos. Cell Cycle 2008 Feb 11;7(9).
49. 2008 Epidermal growth factor receptor (EGFR) blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma (STS) cell growth in vitro and in vivo. Clinical Cancer Research. 2008 May 1;14(9):2785-2795.
50. 2008 Soft tissue sarcoma are highly sensitive to AKT blockade; a role for p53 independent up-regulation of GADD45α. Cancer Res. 2008 Apr 15;68(8):2895-903.
51. 2008 Validation of Randomization based on Patient Genotype Results from RTOG 9704 Trial in Pancreatic Cancer and Implications for Future Trial Design. American Society Therapeutic Radiation Oncology
52. 2008 Distinguishing post-treatment changes from recurrent tumor: An example from cholangiocarcinoma. Journal of Medical Case
53. 2008 Research Highlights in prostate cancer. Future Medicine Series, Therapy, 5;19-22
54. 2008 The anti-angiogenic effects of a VEGF Decoy receptor can be monitored in vivo using contrast-enhance dultrasound imaging. Manuscript in preparation
55. 2008 The zebrafish Delta113p53 isoform is essential for embryonal development and counteracts lethal effects caused by full-length and DeltaNp53. Manuscript inpreparation.
56. 2008 Inhibition of VEGFR2 and EGFR by ZD6474 or ZD2171 can function as a radiosensitizer in p53 knockdown zebrafish embryos. Manuscript in preparation
57. 2008 Expression signature of the EGFR pathway and its association with prognosis in head and neck squamous cell carcinoma. Manuscript in preparation.
58. 2008 Biomarkers and surrogate endpoints for normal-tissue effects of radiation therapy in a QUANTEC perspective International Journal of Radiation Oncology, Biology, Physics.
59. 2008 Validation of Lysyl Oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma – Radiation Therapy Oncology Group Trial 90-03. Submitted Journal of Clinical Oncology.
60. 2007 VEGF Trap Improves Fractionated Radiotherapy in U87 Glioblastoma: Impact of Scheduling and Dosing. International Journal of Radiation Oncology, Biology, Physic
61. 2007 An emerging model system for human disease and drug discovery. Clinical Pharmacology and Therapeutics
62. 2007 Multifocal Glioblastoma Multiforme Patients Should Be Considered for Phase I-II Clinical Trials ASTRO Translational Symposium
63. 2007 Evaluation of Novel Agents as Radiosensitizers from Laboratory to Clinic. ASCO Educational Book
64. 2007 The impact of percent positive prostate biopsy cores on biochemical outcome in patients with low-risk prostate cancer treated with brachytherapy or three dimensional conformal external beam radiotherapy. Genitourinary Cancers Symposium
65. 2007 A Phase I-II Study of COX-2 Inhibitor, Celebrex (celecoxib) and Chemoradiation in Patients with Locally Advanced Cervical Cancer: Primary Endpoint Analysis of RTOG 0128. International Journal of Radiation Oncology, Biology, Physics,
66. 2007 Gene expression profiles as markers of aggressive disease - EGFR as a factor. International Journal of Radiation Oncology, Biology, Physics. 69(2 Suppl):S102-5.
67. 2007 Strategic plans to promote translational head and neck cancer research within Radiation Therapy Oncology Group. A report for the Translational Research Program. International Journal of Radiation Oncology, Biology, Physics, Vol 69, pp S67 S78
68. 2007 Cox-2 Expression Predicts Prostate Cancer Outcome: An Analysis of Radiation Therapy Oncology Group Trial 92-02. Lancet Oncology
69. 2007 Efficacy and Patterns of Failure for Locally Advanced Cervix Cancer Treated with Celebrex (celecoxib) and Chemoradiation. International Journal of Radiation Oncology, Biology, Physics
70. 2007 Activated EGFR signature correlates with presence of the increased EGFR gene copy number in HNSCC Annual Meeting American Association of Cancer Research
71. 2007 A phase I trial of using the proteasome inhibitor bortezomib (Vecade) and concurrent temozolomide and radiotherapy for high grade gliomas. . ASCO Annual meeting
72. 2007 A phase I Trial of Patupilone (Epothilone B) and Concurrent Radiotherapy for CNS Malignancies. Annual Meeting ASTRO
73. 2007 Percent Positive Prostate Biopsy Cores and Biochemical Outcome in Patients with Low-Risk Prostate Cancer Treated with Brachytherapy or Three Dimensional Conformal External Beam Radiotherapy. Mid-Atlantic AUA,
74. 2006 In vivo radioprotection by the fullerene nanoparticle DF-1 as assessed in a zebrafish model Clinical Cancer Research
75. 2006 Uncemented total hip arthroplasty in patients with a prior history of pelvic irradiation for prostate cancer. J Bone Join Surgery 89:798-805
76. 2006 Antisense Inhibition of Cyclin D1 Expression is Equivalent to Flavopiridol for Radiosensitization of Zebrafish Embryos. International Journal of Radiation Oncology, Biology, Physics, Volume 66, No.2,
77. 2006 Regulation of expression of pro-apoptotic Bim in epithelial cells by EGFR activation Annual Meeting ASTRO
78. 2006 Scheduling impacts glioblastoma therapy with VEGF Trap and fractionated radiation. AACR, Annual Meeting
79. 2006 Differential Response to Ultraviolet versus Ionizing Radiation in Zebrafish Embryos Pretreated with Caffeine AACR Annual Meeting
80. 2006 Off-target effects of the p53 inhibitor Pifithrin-related to inhibition of p73 in zebrafish embryos. AACR Annual Meeting
81. 2006 Caffeine protects zebrafish embryos against ultraviolet radiation independently of ATR downstream signaling events. Annual Meeting 2006, Radiation Research Society
82. 2006 Relative radiosensitivities of isogenic U87 cell lines transfected with wtEGFR, EGFRv111 and/or PTEN Annual Meeting 2006
83. 2006 Phase I update of weekly docetaxel, cisplatin, daily celecoxib, concurrent radiotherapy in advanced head and neck cancer Annual meeting of the American Head and Neck Society
84. 2006 Cox-2 Overexpression Predicts Prostate Cancer Outcome: An analysis of RTOG 92-02. Annual Meeting ASTRO
85. 2006 Radiosensitization by Cyclin D1 knockdown phenocopies effects of flavopiridol treatment: Utilization of an in vivo zebrafish vertebrate model. Radiologic Society of North America
86. 2006 Modulation of the radiation response of zebrafish embryos by targeting the VEGFR2 tyrosine kinase using ZD6474. Annual Meeting AACR-EORTC-NCI
87. 2006 Cox-2 Overexpression In Pretreatment Diagnostic Tissue Is Associated With Prostate Cancer Outcome in RTOG 92-02. International Meeting on Cancer Molecular Markers, NCI-EORTCAACR,
88. 2006 Improvement of colorectal tumor control by combining the antiangiogenic agent, ZD6474 (ZACTIMA), with radiotherapy and the chemotherapeutic agent, irinotecan in the LoVo human colorectal cancer xenograft model. AACR-EORTC-NCI Molecular Targets, Prague, Czech Republic
89. 2006 MONITORING THE EFFECT OF VEGF TRAP ON MELANOMA TUMOR VASCULARITY USING CONTRAST ENHANCED ULTRASOUND IMAGING. American Institute of Ultrasound in Medicine
90. 2006 Malignant transformation of immortalized human keratinocytes through deregulated NF-B signaling. u AACR Annual Meeting
91. 2006 The fullerene DF-1 demonstrates general and organ specific radioprotective effects in a zebrafish model. AACR, Annual Meeting
92. 2006 Looking for new targets for prostate cancer therapy: Nuclear factor kappa B and CXCR4 co-expression in prostate specimens from RTOG-8610 ASCO Annual Meeting
93. 2006 A phantom study to compare 2D electronic portal imaging with 3D kV cone-beam imaging. American Association of Physicists in Medicine Annual Meeting
94. 2006 Celebrexâ„¢ (celecoxib) and Chemoradiation in Patients with Locally Advanced Cervical Cancer. An Efficacy Report of RTOG 0128. Annual Meeting ASTRO
95. 2006 Evaluation of radioprotection by superoxide dismutase mimetics and nanoparticle fullerenes using a zebrafish model system. Annual Meeting ASTRO
96. 2006 Differential roles of p53 family members in radiation sensitivity of zebrafish embryo. Annual Meeting ASTRO
97. 2006 In vivo evaluation of MRx-1024, a small molecule radioprotector in zebrafish and mouse models. Annual Meeting ASTRO
98. 2006 Modulation of the radiation response of zebrafish embryos by targeting the VEGF receptor-2 (KDR) tyrosine kinase. Annual Meeting ASTRO
99. 2006 Radiation sensitization of human cervical cancer by Proteasome inhibitor Velcade (Bortezomib). Annual Meeting ASTRO
100. 2006 Differential effects of EGFR and NF-κB in tumorigenesis and radioresistance in epithelial cancers. Annual Meeting ASTRO
101. 2005 A Phase I-II Study of COX-2 Inhibitor, Celebrex (celecoxib) and Chemoradiation in Patients with Locally Advanced Cervical Cancer: Primary Endpoint Analysis of RTOG0128. ASTRO Annual Meeting
102. 2005 Coordinate regulation of cell cycle regulatory genes in zebrafish development: functional consequences of cyclin D1 knockdown with morpholino phosphorodiamidate and hydroxyprolyl-phosphono-peptide nucleic acids. Nucleic Acids Research, vol 33
103. 2005 Predicting the future, from trials of the past: EGFR expression and outcome from altered radiation therapy fraction trials. Journal of Clinical Oncology,
104. 2005 Evaluation of Pubic Arch Interference for Prostate Brachytherapy: Evaluation of Planning Permanent Transperineal Prostate Implants from a “Needles-Eye-View” and Potential for Androgen Suppression for Reduction of Interference. Basic and Advanced Techniques in Prostate Brachytherapy. Taylor & Frances Publishers, London UK.
105. 2005 Salvage of Sub-optimal Prostate Seed Implantation: Re-Implantation of Under- Dosed Region of Prostate Base. Basic and Advanced Techniques in Prostate Brachytherapy Taylor & Frances Publishers, London UK.
106. 2005 Basic and Advanced Techniques in Prostate Brachytherapy Taylor & Frances Publishers, London UK.
107. 2005 Factors Predicting for Urinary Incontinence Following Prostate Brachytherapy. Basic and Advanced Techniques in Prostate Brachytherapy Taylor & Frances Publishers, London UK.
108. 2005 Introduction. Basic and Advanced Techniques in Prostate Brachytherapy. Taylor & Frances Publishers, London UK.
109. 2005 Management of Prostate Cancer Research to Practice
110. 2005 A Survey of Radiation Oncology Patients and their Attitudes to a New Generation of Health Communication. Prostate Cancer and Prostatic Diseases
111. 2005 Differentiation and definition of vascular-targeted therapies. Clinical Cancer Research
112. 2005 Involvement of the Fhit Gene in the Ionizing Radiation-activated ATR/CHK1 Pathway. Journal of Cellular Physiology
113. 2005 Novel Use of Zebrafish as a Vertebrate Model to Screen Radiation Protectors and Sensitizers. International Journal of Radiation Oncology, Biology, Physics.
114. 2005 Salvage of Sub-optimal Prostate Seed Implantation: Re-Implantation of Under-Dosed Region of Prostate Base. Brachytherapy 4(2) 163-170,
115. 2005 Effects Of Androgen Suppression And Radiation For Prostate Cancer Suggest A Role For Angiogenesis Blockade. Prostate Cancer and Prostatic Diseases, Volume 8, Number 2
116. 2005 Effect of the Tumor Vascular Damaging Agent, ZD6126 on the Radioresponse of U87 Glioblastoma. Clinical Cancer Research,
117. 2005 CHK1 Affects Cell Sensitivity to Microtubule-targeted Drugs. Journal of Cellular Physiology
118. 2005 . In vivo evaluation of radioprotection by the fullerene CD60_DF1 using a zebrafish model. AACR-EORTC-NCI Meeting
119. 2005 The VEGF Blocker, VEGF Trap, Improves Fractionated Radiotherapy in U87 Glioblastoma xenograft model AACR-EORTC_NCI Meeting
120. 2005 The selective PARP inhibitor, CEP-8983 exhibits significant radiosensitization against radioresistant U87 human glioblastoma xenografts. AACR-EORTC_NCI Meeting
121. 2005 All movements are not created equal in the course of prostate cancer treatment. ASTRO Annual Meeting
122. 2005 A Phase I Study of Gefitinib (Iressa) In Combination with Hypofractionated Thoracic Radiation Therapy (HRT) with Stereotactic Body Frame (SBF) Immobilization in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): Preliminary Report on the First RT Dose Level ASTRO Annual Meeting
123. 2005 Knock down of p53 suppresses radiation-induced malformations and zebrafish embryo survival. Radiation Research Annual Meeting
124. 2005 A Phase I Study of Gefitinib (Iressa) In Combination with Hypofractionated Thoracic Radiation Therapy (HRT) with Stereotactic Body Frame (SBF) Immobilization in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): Molecular Pathogenesis of Lung Cancer" meeting
125. 2005 Phase I Study of Weekly Docetaxel (T), Cisplatin (P) with Daily Celecoxib (C) and Concurrent Radiotherapy (RT) for Patients with Locally Advanced Head and Neck Cancer (HNC). ASCO
126. 2005 Tumor Radiosentization by Apaziquone (EO9, EOquin). AACR
127. 2005 Improvement of fractionated radiation therapy combination with a VEGF blocker, VEGF Trap.
128. 2005 Coordinate Regulation of Cell Cycle Regulatory Genes and Functional Consequence of Cyclin D1 Knockdown in Zebrafish: A Novel Model to Investigate the Radiation Response in Vertebrates. Gordon Conference in Radiation Oncology
129. 2005 Hydroxyprolyl/phosphono peptide nucleic acid knockdown of cyclin D1 in developing zebrafish embryos. First International Symposium on Biomolecules and Related Compounds: Chemistry, Biology and Applications
130. 2005 Integration of pathways to cell survival in epidermal keratinocytes – an emergent role for TNF-alpha/NFkappaB signaling Keystone Symposium on Microenvironment
131. 2005 Combined treatment with EGFR and COX-2 inhibitors synergistically inhibit apoptosis in HER-2/neu overexpressing breast cancer cells. International Conference on Tumor Progression and Therapeutic Resistance
132. 2005 Pennsylvania Neurosurgical Society, Hershey PA. Short-term results of planned volume staged gamma knife radiosurgery for cerebral AVMs Feasibility and toxicity
133. 2004 Isoeffect analysis for additional seed implant or external beam radiation supplementing an initial prostate implant using linear-quadratic model. Accepted for oral presentation International Conference on the Use of the Computers in Radiation Therapy
134. 2004 Novel Use Of Zebrafish As A Model For Screening Radiation And Protectors And Sensitizers Accepted, Radiation Research Meeting
135. 2004 The Contribution of Epidermal Growth Factor Receptor (EGFR) Signaling Pathway to Radioresistance in Human Gliomas: A Review of Preclinical and Correlative Clinical Data. International Journal of Radiation Oncology, Biology, Physics.
136. 2004 Factors Predicting for Urinary Incontinence Following Prostate Brachytherapy. International Journal of Radiation Oncology, Biology, Physics
137. 2004 Prostate-Specific Antigen (Psa) Doubling Time As A Surrogate Marker For Evaluation Of Oncologic Drugs To Treat Prostate Cancer. Clinical Cancer Research
138. 2004 Reanalysis of approved cancer drugs: old drugs Clinical Cancer Research, Vol. 10, 3897–3907
139. 2004 Improving Tumor Response to Radiotherapy by Targeting Angiogenesis Signaling Pathways. Hematology Oncology Clinics of North America, volume 18, pp 1039-1057
140. 2004 Assessment of angiogenesis: implications for ultrasound imaging Ultrasonics
141. 2004 Differential Sensitivity Of Zebrafish Embryos To Ultraviolet Versus Ionizing Radiation Associated With Differential Expression Of Dna Repair Enzymes. Accepted as a late-breaking poster presentation, American Association for Cancer Research Annual Meeting
142. 2004 Forward: Epidermal growth factor receptor inhibitors and cancer therapeutics. Int. J. Radiation Oncology Biol. Phys
143. 2004 Targeting the epidermal growth factor receptor in cancer-rationale for therapeutic ratio. International Journal of Radiation Oncology, Biology, Physic
144. 2004 Factors Predicting For Urinary Incontinence Following Prostate Brachytherapy. American Society for Therapeutic Radiology and Oncology 43rd Annual Meeting,
145. 2004 Differential Sensitivity of Zebrafish Embryos to Distinct Classes of DNA-Damaging Agents associated with Differential Expression of DNA Repair Enzymes. American Society for Therapeutic Radiology and Oncology 43rd Annual Meeting,
146. 2004 Resistance Of U87 Glioblastoma To The Vascular- Targeting Agent, ZD6126: Reversal Of Resistance By The Nos Inhibitor, L-NNA. Accepted
147. 2004 Extracellular Matrix Components Modulate Radiosensitization Of Transformed Keratinocytes Egfr Inhibition
148. 2004 Involvement Of Chk1 Pathway In Protecting Cells From Taxotere-Induced Killing. AACR
149. 2004 Cancer of the Oropharynx. In: Textbook of Radiation Oncology W. B. Saunders Company,
150. 2004 COX-2 dependents effects of the cyclooxygenase (COX)- 2 inhibitor SC236 when combined with ionizing radiation in mammary tumor cells derived from HER-2/neu mice. Molecular Cancer Therapeutics
151. 2004 Novel Use Of Zebrafish As A Vertebrate Model To Screen Radiation Sensitizers And Protectors. American Society for Therapeutic Radiology and Oncology 43rd Annual Meeting
152. 2004 Salvage Of Sub-Optimal Prostate Seed Implantation: Re-Implantation Of Under- Dosed Region Of Prostate Base. American Society for Therapeutic Radiology and Oncology 43rd Annual Meeting
153. 2004 Differential Sensitivity Of Zebrafish Embryos To Ultraviolet Versus Ionizing Radiation Associated With Differential Expression Of Dna Repair Enzymes. Accepted as a late-breaking poster presentation American Association for Cancer Research Annual Meeting
154. 2004 Role of tumor hypoxia and NO in U87 glioblastoma radioresistance to the vascular targeting agent, ZD6126. 2nd Annual Meeting Vascular Targeting agents
155. 2004 Factors Predicting For Urinary Incontinence Following Prostate Brachytherapy. Accepted for Oral Presentation European Society for Therapeutic Oncology
156. 2004 Image registration technique based on point landmarks and voxel similarity measures for Gamma Knife radiosurgery treatment planning. AAPM Annual Meeting
157. 2003 The Probability Of Late Rectal Morbidity In 125I Prostate Brachytherapy. The Probability Of Late Rectal Morbidity In 125I Prostate Brachytherapy.
158. 2003 Safety and Tolerability of Low-Dose Irradiation for the Management Of Gynecomastia Caused By Antiandrogen Monotherapy. Lancet Oncology
159. 2003 Targeting Angiogenic Processes by Combination Low Dose Paclitaxel and Radiation Therapy. American Journal of Clinical Oncology
160. 2003 Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: Exploring mechanisms of interaction Clinical Cancer Research
161. 2003 A Detailed Examination of the Difference between Planned and Treated Margins in I-125 Permanent Prostate Brachytherapy. Brachytherapy, Volume 2, Issue 4, 223-228
162. 2003 Novel Use Of Zebrafish As A Model For Screening Radiation Protectors And Sensitizers. American Association for Cancer Research Radiation Biology Meeting
163. 2003 RTOG Symposium COX-2 Inhibitors and Cancer Therapeutics. American Journal of Clinical Oncology.
164. 2003 Is It Necessary To Eliminate The Posterior Dose Margin In Prostate Brachytherapy To Achieve An Acceptably Low Risk Of Late Rectal Morbidity? ? International Journal of Radiation Oncology, Biology, Physics, Volume
165. 2003 COX-2 Inhibitors and Cancer Therapeutics: Potential Roles for Inhibitors of COX-2 in Combination With Cytotoxic Therapy Reports From a Symposium Held in Conjunction With the Radiation Therapy Oncology Group June 2001 Meeting. American Journal of Clinical Oncology,
166. 2003 Cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) expression in human Pituitary Macroadenomas. American Journal of Clinical Oncology.
167. 2003 Cyclooxygenase-2 (COX-2) expression in human meningioma as a function of tumor grade. Am J Clin Oncol
168. 2003 The Egfr Inhibitor Zd 1839 (Iressa) Sensitizes Human Melanoma Cells To Hyperthermia. American Society for Therapeutic Radiology and Oncology 45th Annual Meeting
169. 2003 The Inhibition Of Epidermal Growth Factor Receptor (Egfr) Tyrosine Kinase Is Protective In A Murine Model Of Estrogen Receptor Negative Breast Cancer. American College of Surgeons Surgical Journal Forum
170. 2003 Vascular Endothelial Growth Factor (VEGF) Expression In Locally Advanced Prostate Cancer (LAPC): American Society for Therapeutic Radiology and Oncology 45th Annual Meeting
171. 2003 Improvement Of Tumor Control By Combining A VEGF BlockeR, VEGF Trap With Radiation Therapy. Accepted, AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference Annual Meeting
172. 2003 Extracellular Matrix Composition Modulates Radiation Sensitivity Induced By EGFR Blockade In Transformed Keratinocytes. Accepted, AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference Annual Meeting
173. 2002 Linear Peripheral Loading Of Radioactive Seeds For Transperineal Implantation Brachytherapy For Prostate Cancer. Medical Physics
174. 2002 Impact Of Post-Implant Edema On V100 And D90 In Prostate Brachytherapy: Can Implant Quality Be Predicted On Day 0? International Journal of Radiation Oncology, Biology, Physics
175. 2002 Comparing Contrast Enhanced Ultrasound To Immunohistochemical Markers Of Angiogenesis In A Human Melanoma Xenograft Model: Preliminary Results. Ultrasound Med Biol
176. 2002 Critical Evaluation Of Hormone Therapy For Carcinoma Of The Prostate. Urology, Volume 60
177. 2002 Cyclooxygenase 2 (COX-2) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 86-10 L International Journal of Radiation Oncology Biology Physics,
178. 2002 Endothelial Cells Exhibit A Proton Transport Phenotype Best Exploitable In The Acidotic Regions Of Tumors 2002 Annual Meeting of Radiation Research.
179. 2002 Preclinical Studies Of Recombinant Human Angiostatin And Radiotherapy. Annual Meeting of the American Association of Cancer Research.
180. 2002 Ultrasound Imaging Of Angiogenesis And Anti-Angiogenesis Therapy Euroson
181. 2002 Cyclooxygenase-2 (Cox-2) Expression In Human Pituitary Macroadenomas: A Potential Target For Therapy. Presented at the Annual Meeting of the American Association of Clinical Oncology
182. 2002 Targeting Angiogenic Processes by Combination COX-2 inhibition and Ionizing Radiation Humana Press, Totowa NJ
183. 2002 Cyclooxygenase-2 (Cox-2) Expression In Human Meningioma As A Function Of Malignant Progression And Potential Target American Association of Clinical Oncology
184. 2002 Phase I Trial Results Of Recombinant Human Angiostatin Protein (RHA) And External Beam Radiation Therapy (EBRT). Annual Meeting of the American Society of Clinical Oncology
185. 2002 Comparing Contrast-Enhanced Ultrasound To Angiogenic Markers From Melanoma In A Murine Model. 8th Ultrasound Contrast Symposium
186. 2002 Docetaxol (Taxotere) Increases Tumor Oxygen Tension: Potential For Radiosensitization 94th Annual meeting of the American Association of Cancer Research.
187. 2002 Induction Of Tumor Hypoxia In A Human Glioblastoma Xenograft Model By The Vascular Targeting Agent 94th Annual meeting of the American Association of Cancer Research.
188. 2001 Phase I Trial Results And Preclinical Studies Of Recombinant Human Angiostatin (Rha) And Radiotherapy. American Association for Cancer Research-NCI-EORTC Annual Meeting
189. 2001 Targeting Angiogenic Processes by Inhibition of COX-2 with Rofecoxib (Vioxx) and Ionizing Radiation. Accepted for oral presentation, American Society for Therapeutic Radiology and Oncology 43rd Annual Meeting
190. 2001 The Efficiency Of A Stereotactic Body Frame In An Adaptive Radiotherapy Program. American Society for Therapeutic Radiology and Oncology 43rd Annual Meeting
191. 2001 Practical Guidelines For Assessment Of The Risk Of Late Rectal Toxicity In I-125 Prostate Brachytherapy American Society for Therapeutic Radiology and Oncology 43rd Annual Meeting
192. 2001 Phase I Trial Results Of Recombinant Human Angiostatin (rhA) And Radiotherapy. International Journal of Radiation Oncology Biology Physics
193. 2001 A Survey To Evaluate Patient’s Perspective Concerning E-Mail In An Oncology Practice. Accepted for oral presentation American Society for Therapeutic Radiology and Oncology 43rd Annual Meeting
194. 2001 The Effects of Inter- and Intraphysician Variations In Prostate Delineation On Prostatic Volume, Isocenter Location, And Critical Organ DVHS. Annual Meeting, American Association of Physicists in Medicine
195. 2001 Prediction Of The 30-60 Day Postimplant Dosimetry Of An I125 Implant From Day 0 Ct Scan. Annual Meeting, American Association of Physicists in Medicine
196. 2001 Elevated Cyclooxygenase2 Expression Correlates With Diminished Survival In Carcinoma Of The Cervix Treated With Radiotherapy. Winter Meeting, Radiation Therapy Oncology Group
197. 2001 Does Age And Educational Background Impact The Automony Of Patients Treatment Decisions. American Urological Association, 96th Annual Meeting
198. 2001 Targeting Angiogenic Processes By Rofecoxib (Vioxx) And Ionizing Radiation. Translational Research Program Radiation Therapy Oncology Group, Winter Meeting
199. 2001 Targeting Angiogenic Processes By Combination Rofecoxib And Ionizing Radiation. American Journal of Clinical Oncology
200. 2001 Can Extraprostatic Extension Be Treated By Permanent Prostate Brachytherapy Using Palladium-103? An Analysis Based On Post-Implant Dosimetry. International Journal of Radiation Oncology, Biology, Physics
201. 2001 Translational Research Program of the RTOG (Radiation Therapy Oncology Group). International Journal of Radiation Oncology, Biology, Physics
202. 2001 Multidisciplinary prostate cancer clinic: patient’s perspective. Does Age And Educational Background Impact The Automony Of Patients’ Treatment Decisions? American Urological Association, 96th Annual Meeting
203. 2001 The Effect Of Angiostatin On Intracellular Ph And Lethality In Aortic Ring Sprouts. Accepted Annual Meeting Radiation Research
204. 2001 Expression Of Vegfr-2/Kdr/Flk-1 In Whole Mount Prostatectomy Specimens. 37th Annual Meeting American Society of Clinical Oncology
205. 2001 Comparison Of Contrast Enhanced Ultrasound And Predictors Of Angiogenesis In A Human Xenograft Melanoma Model American Institute of Ultrasound in Medicine Annual Meeting
206. 2001 Targeting Angiogenic Processes By Combination Low Dose Squalamine And Radiation Therapy. 92nd Annual Meeting of the American Association of Cancer Research
207. 2001 Evaluating The Anti- Angiogenic Properties Of Docetaxel (Taxotere) In Combination With Ionizing Radiation. 92nd Annual Meeting of the American Association of Cancer Research
208. 2001 Prostate Cancer: The Factors That Influence Patients Treatment Decisions. American Urological Association, 96th Annual Meeting
209. 2001 Acidification Enhances The Effect Of Human Recombinant Angiostatin Human Endothelial Cells. 37th Annual Meeting American Society of Clinical Oncology
210. 2001 Matrix Protein Modulate The Matrix Proteins Modulate The Cell Surface Expression Of Atp-Synthase Affecting Angiostatin Activity 37th Annual Meeting American Society of Clinical Oncology
211. 2001 Treatment Of A Mammary Tumor Cell-Line, Nmf 11.2, To A Select Cyclooxygenase (Cox)-2 Inhibitor Improves The Response To Radiation. 93rd Annual meeting of the American Association of Cancer Research.
212. 2001 Increasing Hypoxia Correlates With Increased Expression Of The Angiogenesis Marker VEGF Inhuman Prostate Carcinoma. Urology
213. 2001 Defining A Future Role For Radiogenetic Therapy. Cancer Treatment Reviews
214. 2001 Does Hormonal Therapy Influence Sexual Function In Men Receiving 3D Conformal Radiation Therapy For Prostate Cancer? International Journal of Radiation Oncology, Biology, Physics,
215. 2001 Elevated COX-2 Expression In Cervix Carcinoma: Reduced Cause-Specific Survival And Pelvic Control. American Journal of Clinical Oncology
216. 2001 Dosimetric Analysis Of Urinary Morbidity Following Prostate Brachytherapy (I-125 Vs. Pd-103) Combined With External Beam Radiation Therapy. International Journal of Cancer
217. 2001 Young investigators workshop-radiation research program, radiation oncology sciences program, National Cancer Institute, NIH, August 1–2 2000. Prepared by the workshop participants Int. J. Radiation Oncology Biol. Phys
218. 2001 Inhibition Of Angiogenesis By Continuous Low Dose Taxanes Causes Growth Delay Of Choriocarcinoma (Jeg-3) In Nude Mice. 93rd Annual meeting of the American Association of Cancer Research.
219. 2001 An Automated Assay Measuring Early Stage Tube Formation For Use In Assessing Anti-Angiogenic Agents 93rd Annual meeting of the American Association of Cancer Research.
220. 2001 “Inhibition Of Angiogenesis Using Rofecoxib (Vioxx) And Ionizing Radiation" European Cancer Conference - ECCO 11, Lisbon Portugal
221. 2000 Targeting Angiogenesis By Paclitaxel-Induced Radiosensitization Of Endothelial Cells Experimental and Clinical Regulation of Angiogenesis
222. 2000 A Dose Volume Histogram Comparison Of Inter- And Intra-Physician Variation In 3D Conformal Radiation Therapy Treatment Planning For Prostate 86th Scientific Assembly and Annual Meeting of the Radiological Society of North America
223. 2000 Doses Isotope Selection Affect Urinary Symptoms After Combined Conformal Radiotherapy And Permanent Prostate Implant? An Evaluation Of Patients Treated With Either Pd-103 Or I-125 For Implant Boost Annual Meeting of the Radiological Society of North America
224. 2000 Does Isotope Selection Matter For Permanent Implants? An Evaluation Of Pd-103 Vs. I-125 Based On Radiobiological Effectiveness American Society for Therapeutic Radiology and Oncology
225. 2000 Inhibition Of Angiogenic Processes In Endothelial Cells By Docetaxel (Taxotere) And Paclitaxel (Taxol) Induced Radiosensitization: A Potential Anti- Angiogenic Strategy American Society for Therapeutic Radiology and Oncology
226. 2000 Can Extraprostatic Extension Be Treated By Permanent Prostate Brachytherapy Using Palladium-103? An Analysis Based On Post-Implant Dosimetry. Presented, 42nd Annual Meeting American Society for Therapeutic Radiology and Oncology
227. 2000 . Increasing Hypoxia Correlates With Increased Expression Of The Angiogenesis Marker, Vegf Inhuman Prostate Carcinoma. Presented, 42nd Annual Meeting American Society for Therapeutic Radiology and Oncology
228. 2000 Does Isotope Selection Matter For Permanent Implants? An Evaluation Of Pd-103 Vs. I-125 Based On Radiobiological Effectiveness American Brachytherapy Society Meeting
229. 2000 Targeting Angiogenesis By Paclitaxel-Induced Radiosensitization Of Endothelial Cells. Presented 91st Annual Meeting American Association for Cancer Research
230. 2000 The Multidisciplinary Clinic Approach to Prostate Cancer Counseling and Treatment. Seminars in Urologic Oncology
231. 2000 Isotope Selection For Permanent Prostate Implants? An Evaluation Of Pd-103 Vs. I- 125 Base On Radiobiological Effectiveness And Dosimetry. Seminars in Urologic Oncology
232. 2000 Is There A Role For Antibiotic Prophylaxis In Transperineal Interstitial Permanent Prostate Brachytherapy. Techniques in Urology
233. 2000 Can The Cost Of Permanent Prostate Implants Be Reduced? An Argument for Peripheral Loading with Higher Strength Seeds. Techniques in Urology
234. 2000 The Impact of Postimplant Edema on Urethral Dose in Prostate Brachytherapy. International Journal of Radiation Oncology, Biology, Physics.
235. 2000 Determination of the Urethral Dose in Prostate Brachytherapy When the Urethra Cannot Be Visualized In the Post-Implant CT Scan. Medical Physics
236. 2000 Peripheral-based loading allows for dose escalation in transperineal interstitial permanent prostate brachytherapy. Isis Medical Media, London UK,
237. 1999 The Efficacy Of Early Adjuvant Radiation Therapy For Pt3no Prostate Cancer: A Matched-Pair Analysis. International Journal of Radiation Oncology, Biology, Physics.
238. 1999 What Is The Radial Margin For High Risk Prostate Cancer Patients Treat With A Permanent Prostate Brachytherapy Implant Boost: An Analysis Based On Post-Implant Dosimetry Accepted, 85th Scientific Assembly and Annual Meeting of the Radiological Society of North America
239. 1999 Comparison Of The Ctc And Rtog Acute Toxicity Scoring Systems In Women With Gynecologic Malignancies Treated With Concurrent Chemoradiation 85th Scientific Assembly and Annual Meeting of the Radiological Society of North America
240. 1999 Indium-111-8-Hydroxiquinolone (Oxine) And In-111- Mercaptopyridine-N-Oxide (Merc) Are Revisited: This time for therapy. Annual Meeting of the Society for Nuclear Medicine
241. 1999 DO Alpha-Blockers Have An Impact On The Urinary Symptoms After Prostate Brachytherapy? An Observational Study With Tamsulosin International Journal of Radiation Oncology Biology Physics, 45:3 (Suppl. 1):431
242. 1999 Effect Of Post-Implant Edema On The Rectal Dose In Prostate Brachytherapy. Accepted to American Brachytherapy Society Annual Meeting
243. 1999 What Is The Optimal Method For Scoring The Urinary Symptoms After Prostate Brachytherapy? A Comparison Of The Common Toxicity Criteria And The American Urological Association Symptom Score the American Association of Clinical Oncology Annual Meeting,
244. 1999 A Dynamic Model For The Estimation Of Optimum Timing Of Computed Tomography Scan For Dose Evaluation Of I-125 Or Pd-103 Seed Implant Of Prostate. International Journal of Radiation Oncology, Biology, Physics.
245. 1999 The Impact Of Edema On Planning I-125 And Pd-103 Prostate Implants. Medical Physics
246. 1999 Determination Of The Urethral Dose In Prostate Brachytherapy When The Urethra Is Not Visualized In The Post-Implant Ct Scan Medical Physics. 26:1146
247. 1999 Use Of Androgen Suppression For Reduction Of Pubic Arch Interference In Patients Being Considered For Prostate Brachytherapy: Evaluation Of Planning Permanent Transperineal Prostate Implants, From A "Needles-Eye-View". Accepted American Brachytherapy Society Annual Meeting
248. 1999 Does Post-Implant Edema Impact On The Urethral Dose After Prostate Brachytherapy? Accepted American Brachytherapy Society Annual Meeting
249. 1999 Faith Nathan, Robert Peterson, Maryanne Baltish, Maria Smirigliano, and Richard K. Valicenti. Multidisciplinary Clinic Approach To Prostate Cancer. Mid-Atlantic Section American Urological Association, 57th Annual Meeting
250. 1999 Variation Of Clinical Target Volume Definition In Three-Dimensional Conformal Radiation Therapy For Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics
251. 1999 Effect of Post-Implant Edema on The Rectal Dose In Prostate Brachytherapy. International Journal of Radiation Oncology, Biology, Physics.
252. 1999 Optimum Timing for Image-Based Dose Evaluation of I-125 and Pd- 103 Prostate Seed Implants. International Journal of Radiation Oncology, Biology, Physics.
253. 1999 Impact Of Post-Implant Edema On Dose Coverage In Prostate Brachytherapy: Can Implant Quality Be Assessed On Day 0 ? International Journal of Radiation Oncology Biology Physics, Special Issue, 45:3 (Suppl. 1):349
254. 1999 How Does Postimplant Edema Effect The Rectal Dose In Prostate Brachytherapy. Accepted, 85th Scientific Assembly and Annual Meeting of the Radiological Society of North America
255. 1998 Squamous Cell Carcinoma of the Oropharynx. In: Head and Neck Cancer Lippincott-Raven Publishers
256. 1998 Stomach Cancer. In: Textbook of Radiation Oncology W. B.Saunders Company
257. 1998 Oropharyngeal Cancer W. B.Saunders Company
258. 1998 Esophagus Cancer. In: Textbook of Radiation Oncology W. B. Saunders Company
259. 1998 How External Beam Technology Can Be Useful For The Planning Of Permanent Transperineal Prostate Implants, A "Needles-Eye-View", 84th Scientific Assembly and Annual Meeting of the Radiological Society of North America, Chicago
260. 1998 Use Of Androgen Suppression For Reduction Of Pubic Arch Interference In Patients Being Considered For Prostate Brachytherapy: Evaluation Of Planning Permanent Transperineal Prostate Implants, From A "Needles-Eye-View", 84th Scientific Assembly and Annual Meeting of the Radiological Society of North America
261. 1998 Three-Dimensional Multiplanar Transrectal Ultrasound Imaging For Visualization Of Radioactive Seeds For Prostate Brachytherapy 84th Scientific Assembly and Annual Meeting of the Radiological Society of North America
262. 1998 Edema Associated With I-125 Or Pd-103 Prostate Brachytherapy And Its Effect On Post-Implant Dosimetry: An Analysis Based On Serial CT Acquisition International Journal of Radiation Oncology, Biology, Physics
263. 1997 Does The Urethral Angle Change With Leg Position? Implications For Urethral-Based Fluoroscopy-Guided Transperineal Prostate Implants 83rd Scientific Assembly and Annual Meeting of the Radiological Society of North America
264. 1997 Peripheral-Based Loading With Verification By Dose Volume Histograms Of Transperineal Prostate Implants Allows Dose Escalation For Brachytherapy 83rd Scientific Assembly and Annual Meeting of the Radiological Society of North America
265. 1997 The Influence Of Rectal Contrast On Dose Volume Histograms For 3d-Conformal Treatment Of The Prostate 83rd Scientific Assembly and Annual Meeting of the Radiological Society of North America
266. 1997 The Effect Of Treatment Positioning On Normal Tissue Dose In Patients With Prostate Cancer Treated With 3- Dimensional Conformal Radiotherapy. The International Journal of Radiation Oncology, Biology, and Physics.
267. 1997 Effect of Edema on the Post-Implant Dosimetry of An I-125 Prostate Implant: A Case Study. International Journal of Radiation Oncology, Biology, Physics
268. 1997 Urethral-Based Fluoroscopy-Guided Transperineal Prostate Implants, Advantages Over Ultrasound 83rd Scientific Assembly and Annual Meeting of the Radiological Society of North America
269. 1997 Edema Associated With I- 125 Or Pd-103 Prostate Brachytherapy And Its Effect On Post-Implant Dosimetry: An Analysis Based On Serial Ct Acquisition American Brachytherapy Society, Palm Beach
270. 1997 Analysis Of The Loss And Migration Of I-125 And Pd- 103 Seeds After Transperineal Prostate Implants. The Use Of Video-Assisted Cystoscopy For Evaluation And Recovery Of Radioactive Seeds Following Prostate Implantation 83rd Scientific Assembly and Annual Meeting of the Radiological Society of North America
271. 1996 Edema Associated With I- 125 Or Pd-103 Prostate Brachytherapy And Its Effect On Post-Implant Dosimetry: An Analysis Based On Serial Ct Acquisition, accepted 39th Annual Meeting American Association for Therapeutic Radiology and Oncology
272. 1996 Does The Urethral Position Change With Leg Position? Implications For Urethral-Based Ct- Planned Transperineal Prostate Implants 39th Annual Meeting American Association for Therapeutic Radiology and Oncology
273. 1996 Variants Of Human Dihydrofolate Reductase With Substitutions At Leucine 22: Effect On Catalytic And Inhibitor Binding Properties. Molecular Pharmacology
274. 1996 Definition Of The Target Volume After Radical Prostatectomy Based On Ct Driven Image Fusion Technology: Implications For Post-Operative Radiation Therapy 39th Annual Meeting American Association for Therapeutic Radiology and Oncology
275. 1996 A Biomathematical Model For Calculating The Dose Delivered By I-125 Or Pd-103 Seeds To The Edematous Prostate 39th Annual Meeting American Association for Therapeutic Radiology and Oncology
276. 1995 Risk Factors For Impotence In Patients With Carcinoma Of The Prostate Treated With Three Dimensional Conformal Radiation Therapy. Accepted for oral presentation 37th Annual Meeting American Association for Therapeutic Radiology and Oncology
277. 1995 Calcium-Dependent Translocation Of Sorcin To Membranes: Functional Relevance In Contractile Tissue FEBS Letters
278. 1995 The Evaluation Of Prostate Specific Antigen, Bone And Ct Scan In The Determination Of Local And Distant Failure In Patients Treated With Three- Dimensional Conformal Radiation Therapy For Carcinoma Of The Prostate. Accepted for oral presentation 81st Scientific Assembly and Annual Meeting of the Radiological Society of North America
279. 1995 The Clinical Utility Of Prostate-Specific Antigen Velocity And Bone Scan In The Follow-Up For Recurrence Of Disease In Patients Treated With Three-Dimensional Conformal Radiation Therapy For Prostate Cancer. Accepted for oral presentation 81st Scientific Assembly and Annual Meeting of the Radiological Society of North America
280. 1995 The Neuropsychological Effects Of Whole Brain, Partial Brain And Three- Dimensional Conformal External Beam Radiation Therapy In Adult Brain Tumor Patients. Accepted for oral presentation 81st Scientific Assembly and Annual Meeting of the Radiological Society of North America
281. 1993 Manual and automated direct sequencing of products generated by the polymerase chain reaction. In: Methods In Molecular Biology The Humana Press Inc
282. 1993 Effect Of Codon 22 Mutations On Substrate And Inhibitor Binding For Human Dihydrofolate Reductase. Advances in Experimental Medicine and Biology
283. 1993 Relationship between varicocele size and response to varicocelectomy Journal of Urology
284. 1993 Mutation Leading To Antifolate Resistance In Chinese Hamster Ovary Cells Following Exposure To An Alkylating Agent Ethylmethane Sulfonate. Molecular Pharmacology
285. 1993 Polymerase chain reaction analysis of DNA from paraffinembedded tissues. In: Methods In Molecular Biology The Humana Press Inc
286. 1993 Methotrexate Resistance In An In Vivo Mouse Tumor Resulting From A Novel Mutation In The Dihydrofolate Reductase Gene. Proceedings of the National Academy of Sciences
287. 1992 Detection Of Point Mutations In Human DNA By Analysis Of RNA Conformation Polymorphism(S). Nucleic Acids Research
288. 1992 Enzyme Kinetic And Physicochemical Characterization Of A Mutated Dihydrofolate Reductase (Dhfr) Giving Rise To Methotrexate Resistance In A Mouse L1210 Tumor. Proceedings of the 83rd Annual Meeting of the American Association for Cancer Research
289. 1992 Development Of Antifolate Resistance Following Exposure Of Chinese Hamster Ovary Cells To The Alkylating Agent Ethyl Methane Sulfonate. Experimental Hematology 20: (6). 797.
290. 1992 Microsurgical Inguinal Varicocelectomy With Delivery Of The Testis: An Artery And Lymphatic Sparing Technique. The Journal of Urology
291. 1992 Quantitation Of Gene Copy Number And Mrna Using The Polymerase Chain Reaction. Proceedings of the Society for Experimental Biology and Medicine
292. 1992 Ab initio studies of aromatic-aromatic and aromatic-polar interactions as relevant in the binding of substrate and inhibitor to dihydrofolate reductase. International Journal of Peptide Protein Research
293. 1991 A Novel Mutation In The Dihydrofolate Reductase Gene Is Responsible For Methotrexate Resistance In A Mouse L1210 Tumor. Proceedings of the 82nd Annual Meeting of the American Association for Cancer Research
294. 1991 Influence Of Age On The Response To Varicocelectomy. The American Society for Fertility and Sterility
295. 1991 Mutational Localization And Site-Specific Mutagenesis Of The Human Dihydrofolate Reductase Gene. Journal of the American Medical Association, Vol 263, No. 13
296. 1990 Mechanism Of Resistance To Methotrexate In An Hl-60 Subline Proceedings of the 81st Annual Meeting of the American Association for Cancer Research
297. 1990 Identification And Characterization Of A Mutation In The Dihydrofolate Reductase Gene From The Methotrexate Resistant Chinese Hamster Ovary Cell Line, Pro-3 MtxRIII. Proceedings of the 81st Annual Meeting of the American Association for Cancer Research, Washington D.C
298. 1990 Identification And Characterization Of A Mutation In The Dihydrofolate Reductase Gene From The Methotrexate Resistant Chinese Hamster Ovary Cell Line, Pro-3 MtxRIII. Journal of Biological Chemistry
299. 1990 Dihydrofolate Reductase As A Therapeutic Target. The FASEB Journal
300. 1990 Mutational Analysis Of Human N-Ras Genes In Malignant Melanoma: Rapid Methods For Oligonucleotide Hybridization, Manual And Automated Direct Sequencing Of Products The Polymerase Chain Reaction. Genes, Chromosomes & Cancer
301. 1990 Microsurgical Varicocelectomy: An Artery And Lymphatic Sparing Technique. The American Society for Fertility and Sterility
302. 1990 Identification And Characterization Of Mutations In The Dihydrofolate Reductase Gene From Methotrexate Resistant Cell Lines. Associated Medical Schools of New York Research Competition
303. 1990 An Active Site Mutation Is Responsible For Methotrexate Resistance In A Chinese Hamster Ovary Cell Line. Gordon Conference on Experimental Chemotherapy and Clinical Cancer
304. 1990 Gene Amplification By The Polymerase Chain Reaction Deutsche Medizinische Wochenschrift
305. 1990 Identification And Characterization Of A Mutation In The Dihydrofolate Reductase Gene Responsible For Methotrexate Resistance In Cho Cells. Tenth Annual Vincent duVigneaud Memorial Research Symposium
306. 1989 Detection Of A Single Base Mutation Of The Human Dihydrofolate Reductase (Dhfr) Gene Using The Polymerase Chain (Pcr) Reaction. The American Association for Cancer Research
307. 1989 Detection Of A Single Base Mutation In The Human Dihydrofolate Reductase Gene From A Methotrexate Resistant Cell Line Using The Polymerase Chain Reaction. The Polymerase Chain Reaction. Cancer Communications
308. 1989 Resistance To Methotrexate In Experimental Models And In Patients. Chemistry and Biology of Pteridines
309. 1989 Mutations At Hydrophobic Residues In Dihydrofolate Reductase Chemistry and Biology of Pteridines
310. 1989 On the mechanism of methotrexate action in rheumatoid arthritis. In: Methotrexate Therapy in Rheumatic Disease. W. S. Wilke Marcel Dekar
311. 1989 The Influence Of Varicocele Size On Response To Surgical Ligation. The American Urological Association 85th Annual Meeting. Journal of Urology
312. 1989 Microsurgical Varicocelectomy: 403 Cases. Journal of Urology 143: (4 Suppl
313. 1989 Resistance To Methotrexate (Mtx) In Experimental Models And In Patients. 9th International Symposium Pteridines and Folic Acid Derivatives
314. 1989 Analysis Of The Dihydrofolate Reductase (DHFR) Gene In Malignant Cells Of The Cerebrospinal Fluid (CSF). The American Society of Hematology
315. 1989 Mutational Localization And Site-Specific Mutagenesis Of The Human Dihydrofolate Reductase Gene. Eastern Student Research Forum
316. 1989 Use Of PCR To Detect Single Base Mutations In The Human Dihydrofolate Reductase (Dhfr) Gene. Meeting on the Polymerase Chain Reaction: Methodology and Applications. Journal of Cellular Biochemistry, Supplement 13E. 281.
317. 1989 . Mechanisms Of Methotrexate Resistance In Blast Cells Of Patients With Acute Lymphocytic (ALL) And Acute Myelocytic Leukemia (AML). Symposium on Mechanisms of Drug and Radiation Resistance of Tumor Cells
318. 1989 Tab Linker And Site-Specific Mutagenesis Of The Human Dihydrofolate Reductase Gene. Symposium on Protein and Pharmaceutical Engineering, Journal of Cellular Biochemistry,
319. 1989 The Role Of Two Hydrophobic Active Site Residues In The Human Dihydrofolate Reductase By Site-Directed Mutagenesis. Symposium on Protein and Pharmaceutical Engineering Journal of Cellular Biochemistry
320. 1988 Correlation Of Sperm-Bound Antibodies With Semen Analysis In Infertile Men With Varicoceles. 83rd Annual Meeting of the American Urological Association, Journal of Urology 139: (4 part 2) 170a.
321. 1985 A Study Of 11 Cases Compared With A Series Of 38 Patients With Pyogenic Liver Abscess American Journal of Gastroenterology
322. 1983 Periileostomy Fistulae In Crohn's Disease Annals of Surgery
323. 1981 Noninvasive Detection Of Left Ventricular Dysfunction With A Portable Electrocardiographic Gated Scintillation Probe Device American Journal of Cardiology


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.